10X Capital Venture Acquisition Corp. III
VCXB-WT
New York Stock Exchange0.01
USD
-0.02
- -
CIK
0001848948
Return %
Stock
S&P500
1Y
-72.33
18.02
3Y
-79.25
64.11
5Y
-79.25
72.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Weisburd
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001848948
- Similar Companies
- Business
- 10X Capital Venture Acquisition Corp. III (VCXB-WT) is a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company focuses on high-growth technology and tech-enabled businesses in sectors including consumer internet, ecommerce, software, healthcare, transportation/mobility, financial services, and other industries disrupted by advances in artificial intelligence, automation, data science, ecommerce, and software-as-a-service; it maintains no current operations or revenues. VCXB-WT represents the publicly traded redeemable warrants of the company, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share. Founded in 2021 and headquartered at 1 World Trade Center, 85th Floor, New York, New York, the company went public in January 2022 through an upsized initial public offering of 30 million units priced at $10.00 each, raising $300 million in gross proceeds, with funds held in trust primarily for an initial business combination. Geographically, it targets opportunities domestically in the United States and internationally across global markets. Following its standard SPAC tenor of 12 months plus two 9-month extensions, the company pursued combinations in the biotechnology sector. In August 2023, 10X Capital Venture Acquisition Corp. III announced a business combination agreement with Addimmune, a clinical-stage biotechnology firm developing gene-modified cell therapies including AGT103-T for HIV, at an implied enterprise value of $500 million, supported by a non-binding letter of intent for a committed equity facility of up to $50 million from a Cantor Fitzgerald affiliate. In April 2023, it had executed a non-binding letter of intent for a reverse merger with American Gene Technologies International Inc., also in biotechnology. Both transactions were mutually terminated, with the Addimmune agreement ending on June 21, 2024, and the American Gene Technologies deal similarly abandoned. Unable to complete an initial business combination by the extended deadline, the company announced redemption of all outstanding Class A ordinary shares on July 11, 2024, at $11.13 per share in cash, with trading in shares ceasing on July 12, 2024, and redemption completing on July 17, 2024, resulting in the SPAC's liquidation. As of December 2025, VCXB-WT warrants remain listed and tradable, with no further merger activity reported. The sponsor, affiliated with 10X Capital, an alternative asset management firm leveraging data analytics and AI, holds significant insider ownership at approximately 82%.